Brand Name
Roctavian
Generic Name
Valoctocogene Roxaparvovec-Rvox
View Brand Information FDA approval date: June 29, 2023
Form: Injection
What is Roctavian (Valoctocogene Roxaparvovec-Rvox)?
ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment